https://scholars.lib.ntu.edu.tw/handle/123456789/630967
標題: | Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial | 作者: | Ren, Zhenggang Ducreux, Michel Abou-Alfa, Ghassan K Merle, Philippe Fang, Weijia Edeline, Julien Li, Zhiwei Wu, Lihua Assenat, Eric Hu, Sheng Rimassa, Lorenza Zhang, Tao Blanc, Jean-Frédéric Pan, Hongming Ross, Paul Yen, Chia-Jui Tran, Albert Shao, Guoliang Bouattour, Mohamed Chen, Yajin Meyer, Tim Hou, Jinlin Tougeron, David Bai, Yuxian Hou, Ming-Mo Meng, Zhiqiang Wu, John Li, Vincent Chica-Duque, Sandra ANN-LII CHENG |
關鍵字: | Hepatocellular carcinoma; Immunotherapy; Pretreated patient population; Tislelizumab | 公開日期: | 二月-2023 | 出版社: | KARGER | 卷: | 12 | 期: | 1 | 起(迄)頁: | 72 | 來源出版物: | Liver cancer | 摘要: | Tislelizumab (anti-programmed cell death protein 1 antibody) showed preliminary antitumor activity and tolerability in patients with advanced solid tumors, including hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of tislelizumab in patients with previously treated advanced HCC. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/630967 | ISSN: | 2235-1795 | DOI: | 10.1159/000527175 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。